



STEMCELL UNITED LIMITED
ACN 009 104 330

29 August 2022

Results of Entitlement Offer and Shortfall Notice

Stemcell United Limited (ASX: SCU) ("SCU" or the "Company"), wishes to advise the results of the non-renounceable entitlement offer announced by the Company on 25 July 2022.

Under the terms of the entitlement offer, eligible shareholders were invited to apply for one (1) new fully paid ordinary share in the Company (**New Share**) for every five (5) existing SCU shares held by eligible shareholders at 7.00pm (AEST) on Friday, 29 July 2022 (**Record Date**), at an issue price of A\$0.009 (0.9 cents) per New Share, together with one (1) free attaching SCU option (**New Option**) for every three (3) New Shares issued, at to raise approximately \$1.88m (before costs) (**Entitlement Offer**). The Entitlement Offer closed at 5:00 pm (AEST) on Thursday, 25 August 2022 (**Closing Date**).

The Company received applications from eligible shareholders for 24,803,141 New Shares and 8,267,806 New Options

Acceptances from eligible shareholders totalled \$223,228.60. The results of the Entitlement Offer are as follows:

Item	Number of Shares
Maximum shares offered under the Entitlement Offer (New Shares)	209,958,368
New Shares applied for under the Entitlement Offer	24,803,141
Number of New Shares which were not subject to a valid application under the Entitlement Offer (Shortfall Shares)	185,155,227

The issuance and quotation of the New Shares and New Options under the Entitlement Offer will be deferred pending reinstatement of the Company's securities to official quotation on the ASX. The New Shares issued under the Entitlement Offer will rank equally in all respects with existing SCU shares

In addition, the Company has received applications from institutional, professional and sophisticated investors to take up a total of 16,392,706 of the Shortfall Shares to raise approximately \$147,534.50.

The Board continue to reserve the right to place any of the remaining Shortfall Shares within 3 months of the Closing Date, subject to the requirements of the ASX Listing Rule and the Corporations Act, and will update the market on the issue of additional shares in due course.

As previously stated, the Company's securities will remain suspended until such time as the outstanding matters disclosed in the Quarterly Activities Report announcement to the ASX dated 29 April 2022 have been resolved and the Company has addressed any other requirements of ASX for its securities to be reinstated to official quotation.

- END -

Authorised for lodgement by the Board of the Company

For further information, please visit the SCU website at www.scu.com.sg or contact:

Mr Philip Gu
Stemcell United Limited
Chief Executive Officer
E: enquiry@scu.com.sg

About Stemcell United Limited

Stemcell United Limited (ASX: SCU) is an Asia-Pacific plant-based biotechnology company that is building a food, nutrition, healthcare, cosmetics and personal care business based on plants found in the region, using its proprietary plant genetics and stem cell technology to refine the propagation and cultivation process. SCU's lead programs involve hemp (which has been cultivated in Asia for millennia), tapping into the medicinal attributes of its cannabidiol (CBD) constituent; and sea grapes (or "green caviar"), a tropical aquatic vegetable native to many parts of the Indo-Pacific coast and a staple delicacy in Japan and regions of south-east Asia; and the processing of these crops to make a wide range of products and additives for the global nutrition, healthcare, cosmetics, beauty, personal care and veterinary markets.

Stemcell United is the first foreign company allowed access to the huge China hemp market, while in sea grapes and seaweed, SCU is building a mass-cultivation aquaculture capability in Singapore, with an integrated manufacturing capacity for high-value products. SCU is also leveraging its environmentally friendly technology to develop medicinal, health, beauty and anti-ageing applications of several other plants that are familiar components of traditional Chinese medicine (TCM). Also, SCU has successfully commercialised the processing and production of pharmaceutical grade Resina Draconis product for Asia.